Abstracts tagged "gout"

Abstract Number: 1089 • ACR Convergence 2024
Endothelial Activation in Gout
Michael Toprover¹, Binita Shah², Kamelia Drenkova², Michael Pillinger³ and Michael Garshick⁴, ¹New York University Langone Health, New York, NY, ²NYU Langone Health, New York, NY, ³New York University Grossman School of Medicine, New York,, NY, ⁴NYU Langone Health, Tenafly, NJ
Background/Purpose: Gout is the most common inflammatory arthritis and is associated with increased cardiovascular (CV) disease and cardiovascular mortality. Our prior studies have suggested that…
Abstract Number: 1293 • ACR Convergence 2024
Educational Quality Improvement (QI) Project to Improve Inpatient Purine Restricted Diet Order Placement for Patients Admitted with Gout Flares
OKEOGHENE AKPOIGBE¹, COMFORT ANIM-KORANTENG², BETTINA ESCOLANO³, NI NI LWIN¹, JOANNA PANGILINAN¹ and Amanda Sammut⁴, ¹New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, NY, ²New York City Health and Hospitals/Harlem in Affliation with Columbia University, Bronx, NY, ³New York City Health and Hospitals/Harlem in Affliation with Columbia University, NEW YORK, ⁴New York City Health and Hospitals/Harlem. Rheumatology Department, Chappaqua, NY
Background/Purpose: Gout is a chronic, but treatable, inflammatory disease characterized by intermittent flares involving the deposition of monosodium urate crystals in and around joints. It…
Abstract Number: 2014 • ACR Convergence 2024
Effect of a Whole Food Plant-Based Diet in Patients with Gout: A Pilot Randomized Controlled Trial
Anna Kretova¹, Carlijn Wagenaar¹, Wendy Walrabenstein², Daisy Vedder², Dirkjan van Schaardenburg² and Martijn Gerritsen¹, ¹Reade Rheumatology Center, Amsterdam, Netherlands, ²Amsterdam UMC, Amsterdam, Netherlands
Background/Purpose: An unhealthy diet is an important modifiable risk factor for hyperuricemia and gout and is also associated with obesity and metabolic syndrome (MetS), known…
Abstract Number: 2561 • ACR Convergence 2024
Circulating Proteomic Profiles and Incident Gout Risk: Prospective Cohort Study of >48,000 Men and Women
Natalie McCormick¹, Amit Joshi², Robert Terkeltaub³, Tony Merriman⁴, Matthew Nayor⁵, Chio Yokose⁶ and Hyon K. Choi⁷, ¹Massachusetts General Hospital, Boston, MA, ²Channing Division of Network Medicine, Boston, MA, ³Retired, San Diego, CA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁶Massachusetts General Hospital, Waltham, MA, ⁷Massachusetts General Hospital, Lexington, MA
Background/Purpose: Detailed characterization of the plasma proteome may provide insights into the dynamic molecular changes preceding gout. A previous cross-sectional study of pre-existing gout (n=330…
Abstract Number: 0206 • ACR Convergence 2024
Urate Lowering Therapy to Acute Treatment Ratio (ULTrA) Index – a Novel Quality Indicator Associated with Reduced Hospital Admissions for Gout
May Shuen Tang, Frank Sen Hee Tay, Amelia Santosa, Shikha Kumari, Pamela Lim, Htet Htet Aung, Su Zin Thinn, Peter Cheung and Manjari Lahiri, National University Hospital, Singapore, Singapore
Background/Purpose: Gout is sub-optimally managed with under-prescribed urate lowering therapy (ULT) leading to frequent flares, increased healthcare utilization and cost.To study the burden of gout…
Abstract Number: 0846 • ACR Convergence 2024
Three Novel Metabolomic Signatures of Inflammation for Female Gout Risk: A Prospective Cohort Study over 26 Years
Sharan Rai¹, Hyon K. Choi², Chio Yokose¹ and Natalie McCormick¹, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Lexington, MA
Background/Purpose: Only 20% of those with hyperuricemia develop clinically evident gout, suggesting that other, likely inflammatory, factors influence NLRP3 inflammasome activation and progression to gout.…
Abstract Number: 1090 • ACR Convergence 2024
Hepatic Fibrosis Before and During Intensive Urate-lowering with Pegloticase in the Presence and Absence of Methotrexate Co-therapy
Naomi Schlesinger¹, Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux³ and Peter Lipsky⁴, ¹University of Utah, Salt Lake City, UT, ²Amgen, Inc., Thousand Oaks, CA, ³Amgen, Inc., Deerfield, IL, ⁴AMPEL BioSolutions, Charlottesville, VA
Background/Purpose: Gout is associated with non-alcoholic fatty liver disease (NAFLD),1 with elevated serum urate (SU) and high flare frequency (≥3 flares/yr) contributing.2 The Fib-4 index, calculated from…
Abstract Number: 1343 • ACR Convergence 2024
Heightened Gout Risk in Patients with Rheumatoid Arthritis: A National Cohort Study
Seonyoung Kang¹, Yeonghee Eun², Kyungdo Han³, Jinhyung Jung⁴, Seulkee Lee⁵, Hoon-Suk Cha⁶, Hyungjin Kim⁷, Jaejoon Lee⁵ and Dong Wook Shin⁸, ¹Samsung Medical Center, Gangnam-gu, Seoul, South Korea, ²Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Jongno-gu, Seoul, Republic of Korea, ³Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea, ⁴Department of Medical Statistics, College of Medicine, Catholic University of Korea, Seoul, Republic of Korea, ⁵Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁶Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁷Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, ⁸Department of Family Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul
Background/Purpose: Although gout is a prevalent disease, the coexistence of rheumatoid arthritis (RA) and gout has been considered unusual. Only several case reports describing the…
Abstract Number: 2015 • ACR Convergence 2024
Health-Related Quality of Life in Patients with Gout Receiving Treat-to-Target Urate-Lowering Therapy
Austin Barry¹, Harlan Sayles¹, Lindsay Helget¹, Maria Androsenko², Hongsheng Wu³, Kaleb Michaud¹, Bridget Kramer¹, Jeff Newcomb¹, Mary Brophy³, Anne Davis-Karim⁴, Bryant England¹, Ryan Ferguson³, Michael Pillinger⁵, Tuhina Neogi⁶, Paul Palevsky⁷, James O'Dell¹ and Ted Mikuls¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Department of VA, Newton, MA, ³Veterans Affairs, Boston, MA, ⁴Veterans Affairs, Albuquerque, NM, ⁵New York University Grossman School of Medicine, New York,, NY, ⁶Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁷University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is associated with decreased health-related quality of life (HRQoL). The ACR endorses treat-to-target (TtT) urate-lowering therapy (ULT) for gout with a serum urate…
Abstract Number: 0265 • ACR Convergence 2024
Performance of Two Gout Remission Definitions in a Two-Year Randomized Controlled Trial of Nurse-led Care
Dansoa Tabi-Amponsah¹, Michael Doherty², Aliya Sarmanova³, Weiya Zhang², Sarah Stewart⁴, William Taylor⁵, Lisa Stamp⁶ and Nicola Dalbeth⁷, ¹The University of Auckland, Auckland, New Zealand, ²Academic Rheumatology, School of Medicine, University of Nottingham; Pain Centre Versus Arthritis, University of Nottingham, Nottingham, United Kingdom, ³Roche Diagnostics International, Clinical Development and Medical Affairs, Nottingham, England, United Kingdom, ⁴Auckland University of Technology, Auckland, New Zealand, ⁵The University of Otago, Wellington, Wellington, New Zealand, ⁶University of Otago, Christchurch, Christchurch, New Zealand, ⁷University of Auckland, Auckland, New Zealand
Background/Purpose: To compare the performance of the 2016 preliminary gout remission definition and a simplified gout remission definition in a clinical trial of nurse-led gout…
Abstract Number: 0848 • ACR Convergence 2024
Impact of SGLT2i Initiation on the Need for Urate-Lowering Therapy and Colchicine Among Gout Patients with Type 2 Diabetes:Propensity-Score Matched, Active Comparator, New User Design Study
Gregory Challener¹, kevin sheng-kai ma¹, Minna Kohler¹, Chio Yokose², Janeth Yinh¹, Natalie McCormick¹ and Hyon K. Choi³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Waltham, MA, ³Massachusetts General Hospital, Lexington, MA
Background/Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2is), initially approved for type 2 diabetes (T2D), have been demonstrated to reduce serum urate levels [1-4] and are associated with…
Abstract Number: 1091 • ACR Convergence 2024
Mapping Monosodium Urate Crystal Deposition Within Joints in Tophaceous Gout: A Dual Energy CT Study
Chamaya De Silva¹, César Díaz², Gregory Gamble³, Anne Horne³, Anthony Doyle³, Lisa Stamp⁴ and Nicola Dalbeth³, ¹Health NZ Waitemata, Auckland, New Zealand, ²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: In gout, monosodium urate (MSU) crystal deposition occurs preferentially at certain joints, most frequently the first metatarsophalangeal (MTP) joint. Dual energy CT (DECT) allows…
Abstract Number: 1653 • ACR Convergence 2024
Osteoarthritis Drives Inflammatory Imprinting of Synovial Fibroblasts, Exacerbating Gouty Arthritis Through m6A Modification of S100A4
ZIYI CHEN¹, Yinghui Hua² and Wenjuan Wang¹, ¹Department of Sports Medicine, Huashan Hospital,Fudan University, Shanghai, Shanghai, China (People's Republic), ²Department of Sports Medicine, Huashan Hospital,Fudan University, Shanghai, China (People's Republic)
Background/Purpose: Patients with osteoarthritis (OA) face an elevated risk of future gouty arthritis (GA). To delineate the underlying cellular and molecular mechanisms of OA-driven gout…
Abstract Number: 2016 • ACR Convergence 2024
Treat to Target in Gout Yields Superior Outcomes Compared to Treat to Avoid Symptoms Approach (results from the Gout TrEatment Strategy Overture Trial)
Anusha Moses¹, Martijn Oude Voshaar¹, Tim L.Th. Jansen² and Mart Van De Laar¹, ¹University of Twente, Enschede, The Netherlands, Enschede, Overijssel, Netherlands, ²1VieCuri Medisch Centrum, Venlo, Netherlands
Background/Purpose: Both the European League Against Rheumatism (EULAR) and the American College for Rheumatology (ACR) state that gout can be effectively managed by reducing sUA…
Abstract Number: 0266 • ACR Convergence 2024
Analysis of Gout Remission Definitions in a Randomised Controlled Trial of Colchicine Prophylaxis for People with Gout Initiating Allopurinol
Dansoa Tabi-Amponsah¹, Lisa Stamp², Anne Horne³, Jill Drake⁴, Sarah Stewart⁵, Gregory Gamble³, Keith Petrie¹ and Nicola Dalbeth³, ¹The University of Auckland, Auckland, New Zealand, ²University of Otago, Christchurch, Christchurch, New Zealand, ³University of Auckland, Auckland, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Auckland University of Technology, Auckland, New Zealand
Background/Purpose: To investigate the effect of colchicine prophylaxis on gout remission when commencing urate lowering therapy (ULT), and illness perceptions of people in remission, using…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].